Cargando…

Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene

Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) that has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid metabolism, and blood clotting. Raloxifene significantly improves serum lipids and serum markers of cardiovascular disease...

Descripción completa

Detalles Bibliográficos
Autor principal:	Vogel, Victor G
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682393/ https://www.ncbi.nlm.nih.gov/pubmed/19281053

Ejemplares similares

A Nationwide Study on the Incidence of Breast Cancer in Korean Women with Osteoporosis Receiving Raloxifene Treatment
por: Lee, Jihyoun, et al.
Publicado: (2021)

Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan
por: Kondo, M, et al.
Publicado: (2009)

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer
por: Torrisi, R, et al.
Publicado: (2001)

Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
por: Kim, Yeesuk, et al.
Publicado: (2020)

Effects of Raloxifene Combined with Low-dose Conjugated Estrogen on the Endometrium in Menopausal Women at High Risk for Breast Cancer
por: Carneiro, Andrea Lucia Bastos, et al.
Publicado: (2021)

Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women
por: Um, Mi Jung, et al.
Publicado: (2017)

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)
por: Fujiwara, Saeko, et al.
Publicado: (2014)

Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis
por: Lu, Hsing-Fang, et al.
Publicado: (2020)

Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene
por: da Silva, Benedito B, et al.
Publicado: (2007)

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017)

Effect of Tamoxifen and Raloxifene on the Proliferative Activity of the Breast Epithelium in Premenopausal Women
por: Lucato, Miliana T, et al.
Publicado: (2015)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Raloxifene for older women: a review of the literature
por: Hansdóttir, Helga
Publicado: (2008)

Effect of aerobic exercise and raloxifene combination therapy on senile osteoporosis
por: Zhao, Chengjin, et al.
Publicado: (2016)

Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence
por: Chen, Mingsheng, et al.
Publicado: (2016)

Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction
por: Vogel, Victor G
Publicado: (2015)

A Novel Role for Raloxifene Nanomicelles in Management of Castrate Resistant Prostate Cancer
por: Taurin, Sebastien, et al.
Publicado: (2014)

Formulation Development for Transdermal Delivery of Raloxifene, a Chemoprophylactic Agent against Breast Cancer
por: Vora, Deepal, et al.
Publicado: (2022)

Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment
por: Nagai, Noriaki, et al.
Publicado: (2018)

Women with large breasts are at an increased risk of advanced breast cancer
por: Sellahewa, Chaminda, et al.
Publicado: (2008)

Denosumab Is Superior to Raloxifene in Lowering Risks of Mortality and Ischemic Stroke in Osteoporotic Women
por: Liu, Ting-Chun, et al.
Publicado: (2023)

Tamoxifen for women at high risk of breast cancer
por: Nazarali, Safia A, et al.
Publicado: (2014)

Controlled release of raloxifene by nanoencapsulation: effect on in vitro antiproliferative activity of human breast cancer cells
por: Fontana, Márcia Camponogara, et al.
Publicado: (2014)

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk
por: Newcomb, P A, et al.
Publicado: (2010)

Risk of osteoporosis and fracture in long-term breast cancer survivors
por: Go, Jieon, et al.
Publicado: (2020)

Raloxifene/Vitamin D Combination Therapy vs. Raloxifene Monotherapy on Serum 25-Hydroxy-Vitamin D Level among Postmenopausal Women with Osteoporosis or Osteopenia: A Randomized Controlled Trial
por: Lee, You-Bin, et al.
Publicado: (2022)

Effects of Hormones on Breast Development and Breast Cancer Risk in Transgender Women
por: Berliere, Martine, et al.
Publicado: (2022)

Ductal approaches to assessment and management of women at high risk for developing breast cancer
por: Locke, Imogen, et al.
Publicado: (2004)

Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer
por: Danforth, David N.
Publicado: (2016)

Risk assessment model for invasive breast cancer in Hong Kong women
por: Wang, Feng, et al.
Publicado: (2016)

Honey: A Promising Therapeutic Supplement for the Prevention and Management of Osteoporosis and Breast Cancer
por: Martiniakova, Monika, et al.
Publicado: (2023)

A Survey of Osteoporosis and Breast Cancer Risk Perception among Menopausal and Postmenopausal Women in Hong Kong
por: Chow, Louis WC, et al.
Publicado: (2017)

MRI screening for breast cancer in women at high risk; is the Australian breast MRI screening access program addressing the needs of women at high risk of breast cancer?
por: Schenberg, Tess, et al.
Publicado: (2015)

Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2008)

Comparison of the Prescribing Pattern of Bisphosphonate and Raloxifene in Korean Women with Osteoporosis: From a National Health Insurance Claims Database
por: Kim, Jungmee, et al.
Publicado: (2015)

Investigation of the treatment potential of Raloxifene-loaded polymeric nanoparticles in osteoporosis: In-vitro and in-vivo analyses
por: Guo, Zhonghua, et al.
Publicado: (2023)

Managing Breast Cancer Risk
por: Ong, Kai Ren, et al.
Publicado: (2005)

Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene
por: Ohta, Hiroaki, et al.
Publicado: (2023)

Cardiac risk in the treatment of breast cancer: assessment and management
por: Valachis, Antonis, et al.
Publicado: (2015)

Breast Cancer Risk Prediction in Korean Women: Review and Perspectives on Personalized Breast Cancer Screening
por: Kim, Do Yeun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_90rtlo1dlbli0ivf0gbsnoic86